Imatinib vs Ipilimumab
Imatinib vs Ipilimumab: Overview
This comparison examines the pharmacological differences between Imatinib and Ipilimumab.
Mechanism of Action
Imatinib: Selective inhibitor of BCR-ABL, c-Kit, and PDGFR tyrosine kinases.
Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.
Pharmacokinetics
Half-life: Imatinib β 18 hours; Ipilimumab β 14.7 days.
Chemical Properties
Molecular Formula: Imatinib β C29H31N7O.
Molecular Weight: Imatinib β 493.6030 g/mol.
Type: Imatinib β Small molecule; Ipilimumab β Antibody.